New combo therapy aims to shrink enlarged spleens in myelofibrosis patients
NCT ID NCT07357727
First seen Jan 22, 2026 · Last updated May 03, 2026 · Updated 16 times
Summary
This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a bone marrow cancer that often causes an enlarged spleen and severe symptoms. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a placebo plus ruxolitinib. The main goals are to see if the combination reduces spleen size and eases symptoms after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, Yangcheon Gu, 07985, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
Conditions
Explore the condition pages connected to this study.